Therapeutic Effect of Targeted Hyaluronan Binding Peptide on Neurofibromatosis

s 1. Xue-Ming Xu, Jinguo Chen, Luping Wang, Xu-Fang Pei, Shanmin Yang, Charles B. Underhill and Lurong Zhang: Peptides derived endostatin and angiostatin inhibits tumor growth. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43:1084:5364 2. Luping Wang, Jianjin Wang, Jiyao Yu, Haoyong Ning, Xu-Fang Pei, Jinguo Chen, XueMing Xu, Shanmin Yang, Charles B. Underhill, Lei Liu and Lurong Zhang: Expression pattern of ECM1 in human tumors. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43: 729: 3618 3. Luping Wang, Xu-Fang Pei, Jinguo Chen, Xue-Ming Xu, Shanmin Yang, Ningfei Liu, Charles B. Underhill and Lurong Zhang: A peptide derived from hemopexin-like domain of MMP9 exerts anti-tumor effect. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43: 159:794 4. Shanmin Yang, Jinguo Chen, Xue-Ming Xu, Luping Wang, Shimin Zhang, Xu-Fang Pei, Jing Yang, Charles B. Underhill and Lurong Zhang: Triptolide, a potent antitumor/metastasis agent. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43: 854: 4233 5. Ku-chuan Hsiao, Shanmin Yang, Jinguo Chen, Xue-Ming Xu, Luping Wang, Jing Yang, Charles B. Underhill and Lurong Zhang. A peptide antagonist of Fas acts as strong stimulus for cell proliferation. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43: 706:3502 Charles B. Underhill, Ph.D. and Zhang, Lurong, M.D., Ph.D. DAMD17-01-1-0708 29 6. Jinguo Chen, Xueming Xu, Shanmin Yang, Luping Wang, Charles B. Underhill, Lurong Zhang: Over-expression of tumor necrosis factor-stimulated gene-6 protein (TSG-6) suppresses tumor growth in vivo. Proc. Annu. Meet. Am. Assoc. Cancer Res 2002; 43: 799:3962 7. Jinguo Chen, Glenn D. Prestwich, Yi Luo, Xueming Xu, Shanmin Yang, Luping Wang, Charles B. Underhill and Lurong Zhang.: Inhibition of tumor growth and metastasis by hyaluronan conjugated Taxol. Proc. Annu. Meet. Am. Assoc. Cancer Res 2003; 44:1654 8. Luping Wang, Sunghee Kim, Jinguo Chen, Xue-Ming Xu, Shanmin Yang, Charles B. Underhill, and Lurong Zhang: Decoy TR6 protects tumor cells from apoptosis. Proc. Annu. Meet. Am. Assoc. Cancer Res 2003; 44: 149 9. Xue-Ming Xu, Ningfei Liu, Jinguo Chen, Luping Wang, Shanmin Yang, Charles B. Underhill, and Lurong Zhang. A Hyaluronan Binding Peptide Can Trigger Apoptosis by Antagonizing Members of the Bcl-2 Family. Proc. Annu. Meet. Am. Assoc. Cancer Res 2003; 44: 5589 10. Shanmin Yang, Jinguo Chen, Xue-Ming Xu, Luping Wang, Charles B. Underhill and Lurong Zhang. Liposomal Triptolide inhibits tumor growth at a low dose. Proc. Annu. Meet. Am. Assoc. Cancer Res 2003; 44: 6461 11. Weimin Liu, Ivan Ding, Keqiang Chen, John Olschowka, Lurong Zhang and Paul Okunieff: Elevation of IL-1 and matrix metalloproteinases (MMPs) in radiation induced mouse dermatitis and fibrosis. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 3119 12. Lurong Zhang, Weimin Liu, Xiaoqi Gong, Jian Wang, Dading Fu, Yuanying Jiang, Ivan Ding and Okunieff Paul, Elevation of Hyaluronan After Radiation in Vitro and in Vivo. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004;335 13. Paul Okunieff, Weimin Liu, Jainhua Xu, Keqiang Chen, Lurong Zhang and Ivan Ding: Effect of Cytokines on radiation induced cutaneous toxicity in mice. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 3117 14. Lurong Zhang, Shanmin Yang, Luping Wang, Weimin Liu and Sunghee Kim: Regulation of DcR3 in cancer cells by modulators of protein kinase C. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 3395 15. Luping Wang, Feng Gao, Zeqiu Han, Shanmin Yang, Jinguo Chen, Charles B. Underhill and Lurong Zhang. Alterations of hyaluronan and hyaluronidase induced by Hypoxia. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 3587 16. Jinguo Chen, Xue-Ming Xu, Charles B. Underhill, Shanming Yang, Karen Creswell and Lurong Zhang: Tachyplesin can kill tumor cells by activation of the classical complement pathway. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 4375 17. Shanmin Yang, Jinguo Chen, Charles B. Underhill, Sunghee Kim, Luping Wang, Xu-Ming Xu and Lurong Zhang: Effect of Triptolide on the Telomerase Activity in Human Cancer Cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004,993 Charles B. Underhill, Ph.D. and Zhang, Lurong, M.D., Ph.D. DAMD17-01-1-0708 30 18. Sunghee Kim, Shanmin Yang, Weimin Liu, Xue-Ming Xu and Lurong Zhang: Transcriptional regulation of DcR3 in colon cancer cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004, 3342 19. Shanmin Yang, Luping Wang, Jinguo Chen, Xue-Ming Xu, Sunghee Kim, Charles B. Underhill and Lurong Zhang: Radiation-sensitizing effect of DcR3 siRNA on human colon cancer SW480 cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 4151 20. Ross JS, Sheehan CE, Kallakury BVS, Azumi N, Kim S,Yang S, Zhang L: Immunohistochemical expression of decoy receptor DcR3 in human colorectal and ovarian carcinomas. Proc. Annu. Meet. Am. Assoc. Cancer Res. 2004; 3362 Charles B. Underhill, Ph.D. and Zhang, Lurong, M.D., Ph.D.DAMD17-01-1-0708 31References1. Sakai A: Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells. NipponRinsho 2000; 58(7): 1426-92. Rasmussen SA, Friedman JM: NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000;151(1):33-403. Shen MH, Harper PS, Upadhyaya M: Molecular genetics of neurofibromatosis type 1 (NF1). J MedGenet 1996; 33(1):2-174. Park VM, Pivnick EK: Neurofibromatosis type 1 (NF1): a protein truncation assay yieldingidentification of mutations in 73% of patients. J Med Genet 1998; 35(10):813-205. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89(1):1-66. Feldkamp MM, Angelov L, Guha A: Neurofibromatosis type 1 peripheral nerve tumors: aberrantactivation of the Ras pathway. Surg Neurol 1999 Feb;51(2):211-87. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation of rasproteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356(6371):713-58. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A: Haploinsufficiency for theneurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 1999;18(31): 4450-99. Prayson RA: Bcl-2, bcl-x, and bax expression in dysembryoplastic neuroepithelial tumors. ClinNeuropathol 2000; 19(2): 57-6210. Weiss B, Bollag G, Shannon K: Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. AmJ Med Genet 1999; 89(1): 14-2211. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V: Farnesyltransferase inhibitors block theneurofibromatosis type I (NF1) malignant phenotype. Cancer Res 1995; 55(16):3569-7512. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target foranticancer therapeutic development. J Clin Oncol 1999 Nov;17(11):3631-5213. Gabriel KR: Neurofibromatosis. Curr Opin Pediatr 1997; 9(1): 89-9314. Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL: Fas and Fas ligand interactions in malignantdisease. Int J Oncol 2000; 17(1): 5-1215. Arya J, Finlayson CA, Shames BD, Harken AH, Anderson BO: Stimulated apoptosis as an anti-neoplastic strategy. Surgery 2000; 127(4): 366-916. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000; 21(3): 485-9517. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17(9): 2941-5318. Roth JA, Swisher SG, Meyn RE: p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt)1999;13(10 Suppl 5):148-5419. Lang FF, Yung WK, Sawaya R, Tofilon PJ: Adenovirus-mediated p53 gene therapy for human gliomas.Neurosurgery 1999; 45(5):1093-10420. Brenner C and Kroemer G: Mitochondria –the death signal integrators. Science 2000; 289 (5482): 1150-115121. Marchenko ND, Zaika A, Moll UM: Death signal-induced localization of p53 protein to mitochondria. Apotential role in apoptotic signaling. J Biol Chem 2000 May 26; 275(21):16202-1222. Klein D, Ricordi C, Pugliese A, Pastori RL: Inhibition of Fas-mediated apoptosis in mouse insulinomabetaTC-3 cells via an anti-Fas ribozyme. Hum Gene Ther 2000 May 1;11(7):1033-4523. Shinoura N, Muramatsu Y, Yoshida Y, Asai A, Kirino T, Hamada H: Adenovirus-mediated transfer ofcaspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Exp Cell Res 2000;256(2):423-3324. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil R: Constitutiveexpression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90(1): 12-20 Charles B. Underhill, Ph.D. and Zhang, Lurong, M.D., Ph.D.DAMD17-01-1-0708 3225. Morris G, DeNardo SJ, DeNardo GL, Leshchinsky T, Wu B, Mack PC, Winthrop MD, Gumerlock PH:Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Rajilymphoma growth. Biochem Mol Med 199; 60(2):108-1526. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance.Curr Opin Oncol 1995; 7(6):541-627. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS: Potential use of soluble CD44 in serum asindicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res1994;54(2):422-628. Sy MS, Guo YJ, Stamenkovic I: Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein J Exp Med 1992;176(2):623-729. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH: Soluble hyaluronan receptor RHAMMinduces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 1996;183(4):1663-830. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR,Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277-8531. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH,Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasesby a Lewis lung carcinoma. Cell 1994;79(2):315-2832. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors onmultistage carcinogenesis in mice. Science 1999; 284(5415):808-1233. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis byPEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92(3):391-40034. Miller DR, et al: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advancedcancer. J Clin Oncol. 1998; 16(11):3649-5535. Simone CB, et al: Shark cartilage for cancer. Lancet. 1998; 9; 351(9113): 1440.36. Newman V, et al: Dietary supplement use by women at risk for breast cancer recurrence. The Women'sHealthy Eating and Living Study Group. J Am Diet Assoc. 1998; 98(3): 285-92.37. Ernst E: Shark cartilage for cancer? Lancet. 1998; 24; 351(9098): 298.38. Markman M: Shark cartilage: the Laetrile of the 1990s. Cleve Clin J Med. 1996; 63(3): 179-80.39. Hunt TJ, et al: Shark cartilage for cancer treatment. Am J Health Syst Pharm. 1995; 52(16): 1756, 1760.40. Blackadar CB: Skeptics of oral administration of shark cartilage. J Natl Cancer Inst. 1993; 85(23): 1961-2.41. Mathews J: Media feeds frenzy over shark cartilage as cancer treatment. J Natl Cancer Inst. 1993; 4;85(15): 1190-1.42. Couzin J.: Beefed-up NIH center probes unconventional therapies. Science. 1998;282(5397):2175-643. Oikawa T, et al: A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction andestimation of inhibitory activities toward tumor and embryonic angiogenesis.Cancer Lett.1990;51(3):181-6.44. Lee A, et al: Shark cartilage contains inhibitors of tumor angiogenesis. Science. 1983; 221 (4616):1185-7.45. Langer R. Brem H. Falterman K. Klein M. Folkman J. Isolations of a cartilage factor that inhibits tumorneovascularization. Science; 1976. 193(4247):70-246. Horsman MR, et al: The effect of shark cartilage extracts on the growth and metastatic spread of theSCCVII carcinoma. Acta Oncol. 1998; 37(5): 441-5.47. Moses, M A, Sudhalter, J., and Langer, R.: Identification of an inhibitor of neovascularization fromcartilage. Science 1990; 248: 1408-141048. Moses, M A, Sudhalter, J., and Langer, R.: Isolation and characterization of an inhibitor ofneovascularization from scapular chondrocytes. J. Cell Biol. 1992: 119 (2):473-482 Charles B. Underhill, Ph.D. and Zhang, Lurong, M.D., Ph.D.DAMD17-01-1-0708 3349. Minn, A. J., Velez, P., Schendel, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill, M., andThompson, C. B. (1997). Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 385, 353-357.50. Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M., and Reed, J. C. (1997). Channelformation by antiapoptotic protein Bcl-2. Proc.Natl.Acad.Sci.U.S.A 94, 5113-5118.51. Schlesinger, P. H., Gross, A., Yin, X. M., Yamamoto, K., Saito, M., Waksman, G., and Korsmeyer, S. J.(1997). Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2.Proc.Natl.Acad.Sci.U.S.A 94, 11357-11362.52. Nakamura T, Furunaka H, Miyata T, et al. Tachyplesin, a class of anti-microbial peptide from thehemocytes of the horseshoe crab. Isolation and chemical structure. J Biol Chem. 1988; 263:16709-1671353. Rao AG. Conformation and antimicrobial activity of linear derivatives of tachyplesin lacking disulfidebonds. Arch Biochem Biophys. 1999; 361:127-134.54. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology 2000; 49:159-170.55. Markman M: Shark cartilage: the Laetrile of the 1990s. Cleve Clin J Med. 1996; 63(3): 179-80.56.